Tuesday, April 07, 2026 | 09:15 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch
Sanket Koul

Sanket Koul

Sanket Koul

Sanket Koul is a mass communication graduate with a PG diploma in English Journalism from IIMC Delhi. As a correspondent at Business Standard, he covers the pulse of the social sector, from industry and institutional developments, to the government's latest moves in education, healthcare, pharmaceuticals and medical devices sectors.

Sanket Koul is a mass communication graduate with a PG diploma in English Journalism from IIMC Delhi. As a correspondent at Business Standard, he covers the pulse of the social sector, from industry and institutional developments, to the government's latest moves in education, healthcare, pharmaceuticals and medical devices sectors.

Email

Page 23 - Sanket Koul

US pharma tariffs: CDMOs with innovator exposure likely to take a hit

Branded, patented pharma companies that have not agreed to lower drug prices via MFN agreements will face 100 per cent tariffs

US pharma tariffs: CDMOs with innovator exposure likely to take a hit
Updated On : 05 Apr 2026 | 10:10 PM IST